Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
The ICC U19 Women’s T20 World Cup 2027 is set to commence on January 21,…
Iodine Deficiency Day or World Iodine Deficiency Disorders Prevention Day is celebrated on October 21…
There is an imported case of the Bundibugyo strain of the Ebola virus in the…
On October 21, 2026, the Drugs Controller General of India (DCGI) approved Zytorvi (toripalimab) in…
India was ranked third in the Ipsos Quality of Care Perception Index 2026 after Malaysia…
Jamnagar is a coastal city in the state of the Gujarat and it is emerging…